Halozyme Therapeutics (HALO) PT Raised to $28 at UBS; Momentum to Continue
Tweet Send to a Friend
UBS analyst Andrew Peters reiterated a Buy rating and lifted his price target on Halozyme Therapeutics (NASDAQ: HALO) to $28.00 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
